Clinical trial success for Spark Impact back pain relief product
January 13, 2015
Liverpool based LumbaCurve International, backed by SPARK Impact, manager of The North West Fund for Biomedical, have announced that clinical trials of their innovative back pain relief device have now been completed and the results confirm that LumbaCurve can significantly reduce lower back pain.
An abstract of the independent clinical evaluation, carried out by the University of Central Lancashire Movement Analysis Laboratory, was presented at the Society for Back Pain Research in Dublin annual conference, which concluded that LumbaCurve was significantly more effective compared with standard treatment guidelines currently advocated by the NHS.
LumbaCurve director David Pegg commented, “Needless to say we are delighted with these findings, and as a direct result LumbaCurve has already been taken on by a major European medical distributor, and are now in talks with a potential U.S. partner.
The abstract is to be published in the Bone and Joint Journal and a Journal paper submission to the European Spine Journal is pending.
For further information on the Clinical Evaluation click here